Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Yangxue Qingnao granule + donepezil hydrochloride is a combination therapy that combines a traditional Chinese herbal medicine formula with a conventional acetylcholinesterase inhibitor. The combination has been studied for its effects on cognitive impairment, particularly in mild cognitive impairment (MCI) and vascular dementia. Yangxue Qingnao granule functions to activate blood circulation, remove blood stasis, nourish the blood and liver, and improve cerebral blood flow. Donepezil hydrochloride is an acetylcholinesterase inhibitor that increases acetylcholine levels in the brain. Studies indicate that this combination therapy is more effective than donepezil alone in improving cognitive function without increasing adverse events.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on yangxue qingnao granule + donepezil hydrochloride.